BRCA1 and breast carcinoma: When breast cancer cells and MSCs were simultaneously co-cultured, the therapeutic impact was diminished in vivo due to the upregulation of resistance-related genes (such as MUC1, MYC and BRCA1) in the breast cancer cells after cisplatin pre-treatment [179].